Phenotypic Drug Discovery
Phenotypic drug discovery has been highlighted in the past decade as an important strategy in the discovery of new medical entities. How many marketed drugs are derived from phenotypic screens? From the most recent examples, what were the factors enabling target identification and validation? This book answers these questions by elaborating on fundamental capabilities required for phenotypic drug discovery and using case studies to illustrate approaches and key success factors. Written and edited by experienced practitioners from both industry and academia, this publication will equip researchers with a thought-provoking guide to the application and future development of contemporary phenotypic drug discovery for clinical success.
Phenotypic Drug Discovery, The Royal Society of Chemistry, 2020.
Download citation file:
Digital access
Print format
Table of contents
-
Phenotypic Drug Discovery: A Personal PerspectiveByJonathan A. LeeJonathan A. LeeSearch for other works by this author on:
-
Chapter 1: Phenotypic Drug Discovery: History, Evolution, Futurep1-19ByDavid C. SwinneyDavid C. SwinneySearch for other works by this author on:
-
Chapter 2: Development and Validation of Disease Assays for Phenotypic Screeningp20-36ByAlison O'MahonyAlison O'MahonySearch for other works by this author on:
-
Chapter 3: The Development and Use of Protein and Protein-affinity Libraries for Phenotypic Screeningp37-57ByJames HuntJames HuntSearch for other works by this author on:
-
Chapter 4: CRISPR/Cas-based Functional Genomic Approaches to Phenotypic Screeningp58-82ByBeverley Isherwood;Beverley IsherwoodMedicines Discovery CatapultAlderley ParkUKSearch for other works by this author on:Samantha Peel;Samantha PeelDiscovery Biology, Discovery Sciences, R&D, AstraZenecaCambridgeUKSearch for other works by this author on:Ultan McDermottUltan McDermottSearch for other works by this author on:
-
Chapter 5: Contemporary Techniques for Target Deconvolution and Mode of Action Elucidationp83-103ByMarkus Schirle;Markus SchirleChemical Biology and Therapeutics, Novartis Institutes for BioMedical ResearchCambridgeMA 02139USA[email protected][email protected]Search for other works by this author on:Jeremy L. JenkinsJeremy L. JenkinsChemical Biology and Therapeutics, Novartis Institutes for BioMedical ResearchCambridgeMA 02139USA[email protected][email protected]Search for other works by this author on:
-
Chapter 6: Artificial Intelligence as an Enabler for Phenotypic Drug Discoveryp104-117ByNicole Renaud;Nicole RenaudChemical Biology and Therapeutics, Novartis Institutes for BioMedical Research181 Massachusetts AvenueCambridgeMA 02139USA[email protected][email protected]Search for other works by this author on:Yuan WangYuan WangChemical Biology and Therapeutics, Novartis Institutes for BioMedical Research181 Massachusetts AvenueCambridgeMA 02139USA[email protected][email protected]Search for other works by this author on:
-
Chapter 7: Public–Private Partnerships to Advance Phenotypic Drug Discoveryp118-139ByNeil Carragher;Neil CarragherEdinburgh Cancer Research UK Centre, MRC Institute of Genetics and Molecular Medicine, University of EdinburghEdinburghUK[email protected]Edinburgh Phenotypic Assay Centre (EPAC), University of EdinburghEdinburghUKSearch for other works by this author on:Paul D. Andrews;Paul D. AndrewsNational Phenotypic Screening Centre, School of Life Sciences, University of DundeeDundeeUKSearch for other works by this author on:David Carter;David CarterBiological and Medical Sciences, Oxford Brookes University, HeadingtonOxfordUKSearch for other works by this author on:Denise Barrault;Denise BarraultEdinburgh Cancer Research UK Centre, MRC Institute of Genetics and Molecular Medicine, University of EdinburghEdinburghUK[email protected]National Phenotypic Screening Centre, School of Life Sciences, University of DundeeDundeeUKSearch for other works by this author on:Daniel EbnerDaniel EbnerTarget Discovery Institute, Nuffield Department of Medicine, University of OxfordOxfordUK[email protected]Search for other works by this author on:
-
Chapter 8: Identification of a Novel Class of Small Molecules for Spinal Muscular Atrophy Through High-throughput Phenotypic Screeningp140-159BySusanne E. Swalley;Susanne E. SwalleyBiogen, Inc, Department of Chemical Biology & Proteomics125 Broadway StreetCambridgeMA, 02139United States[email protected]Search for other works by this author on:Atwood K. CheungAtwood K. CheungNovartis Institutes for Biomedical Research, Global Discovery Chemistry22 Windsor StreetCambridgeMA, 02139United StatesSearch for other works by this author on:
-
Chapter 9: Antibody-based Phenotypic Screening – the Discovery of Oleclumab (MEDI9447)p160-174ByKris Sachsenmeier;Kris SachsenmeierAstrazeneca, Oncology R&D, Translational MedicineGatehouse DriveWalthamMA 02451USASearch for other works by this author on:Zachary A. Cooper;Zachary A. CooperAstrazeneca, Oncology R&D, Translational MedicineMedimmune WayGaithersburgMD 20878USASearch for other works by this author on:Steven RustSteven RustSearch for other works by this author on:
-
Chapter 10: Use of Phenotypic Screening in Mice in the Development of a Novel Non-D2-Receptor-Targeting Drug for the Treatment of Schizophreniap175-197ByD. BrunnerD. BrunnerSearch for other works by this author on:
-
Chapter 11: Phenotypic Screening for Drug Discovery in Tuberculosisp198-216ByV. DelormeV. DelormeSearch for other works by this author on:
-
Chapter 12: Why an In Vivo Screening Platform Covering Broad Therapeutic Spectrum is an Ideal Tool for Drug Repositioning: Illustrated by Discovery of a Novel Class of Insulin Sensitizersp217-232ByChristopher A. LipinskiChristopher A. LipinskiSearch for other works by this author on:
-
Chapter 13: Phenotypic Screen Leads to Identification of Novel Post-transcriptional Regulation Machinery for HBVp233-241ByHassan JavanbakhtHassan JavanbakhtSearch for other works by this author on:
Spotlight
Advertisement
Advertisement